Questions about MS? Call us on 0808 800 8000
an image of a stethoscope

Daclizumab New treatment to be available for people with relapsing MS

A new treatment for relapsing MS called daclizumab (also known as Zinbryta) has been recommended by NICE in England and Wales.

A decision will be made for people in Scotland and Northern Ireland over the coming months.

The NICE recommendation is now subject to appeal. But if there are no hold ups, it could be available on the NHS within the next 3 months.

What does this mean for people with relapsing MS?

This means the NHS will have a legal obligation to provide the treatment to anyone with relapsing MS whose health care professional prescribes it to them.

Who can take it?

NICE have approved the treatment for people who have:

  • ‘Active’ relapsing MS that’s been treated with another disease modifying treatment.
  • ‘Rapidly evolving severe’ MS (defined by at least 2 relapses in the previous year and an MRI scan showing new lesions)

It will only be available to people who are unable or unwilling to take alemtuzumab.

Effective treatment

Trials have shown that daclizumab is effective at reducing relapses and the build-up of disability.

The treatment is a monthly injection that you give yourself.

Our Chief Executive Michelle says:

“This is great news for people with relapsing MS.

“This is an effective medicine and the first that people can take by self-injecting once a month. It also offers more choice to people who are currently unwilling or unable to take other MS drugs. We look forward to seeing it become widely available on the NHS in England and Wales.”

Milestone in MS treatment

This is the first new disease modifying therapy to be made available on the NHS since 2014 and means there are now 12 drugs for people with relapsing MS to choose from.

When will there be therapies for progressive MS?

The first NICE appraisals for progressive MS could be published next year. For news and opportunities to contribute to the appraisal process follow us on Facebook and Twitter.